Sharemaestro Newsreel

Hims & Hers Health Inc (HIMS) (Q2 2026) Earnings Call Highlights: Revenue Surges 40% to ...

This article first appeared on GuruFocus. Revenue: Grew nearly 40% year-over-year to more than $753 million in the second quarter. Subscribers: Added 300,000 net new subscribers, ending the quarter with nearly 3 million. Domestic Revenue: Accelerated to 16% year-over-year growth, generating $622 million. International …

SCYNEXIS Swings To Q2 Profit; Expects Phase 1 Topline Data For SCY-770 In Q3 2026;Stock Up

(RTTNews) - SCYNEXIS, Inc. (SCYX), a clinical-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, swinging to a net profit compared to a loss last year. In addition, the company provided an update on its investigational pipeline. Company Profile …

Scynexis Inc earnings beat by $1.14, revenue topped estimates

Scynexis Inc (NASDAQ: SCYX) reported strong second-quarter results, beating analyst EPS estimates by $1.14 with an EPS of $0.630. The company also exceeded revenue expectations, bringing in $240K against a consensus estimate of $80.33K. Despite the positive earnings, Scynexis Inc's stock has seen a …

HIMS Stock Tumbles As Branded GLP-1 Pivot Triggers Margin Hit And One-Time Charges

Harrow Achieves Q2 Revenue Growth, Reiterates 2026 Full-Year Financial Guidance

Harrow announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $70.7 million, a 60 percent sequential increase. The company reiterated its full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 …

Haleon and Singapore's Agency for Science, Technology and Research (A*STAR) Launch New Clinical Study on Women's Metabolic Health in Asia

A new clinical study on the multivitamin and mineral supplement Centrum is designed to generate evidence on metabolic health in midlife Asian women - a group often underrepresented in global nutrition research. The study will contribute to a better understanding of preventive healthcare and …

Hims & Hers Health Q2 Earnings Call Highlights

This article first appeared on GuruFocus. Revenue: Grew nearly 40% year-over-year to more than $753 million in the second quarter. Subscribers: Added 300,000 net new subscribers, ending the quarter with nearly 3 million. Domestic Revenue: Accelerated to 16% year-over-year growth, generating $622 million. International …

How Profit-to-Loss Swing Despite Rising Sales At Harrow (HROW) Has Changed Its Investment Story

Harrow, Inc. (HROW) reported a swing from profit to a net loss in Q2 2026, despite rising sales, with net loss deepening to US$44.87 million over the first six months of 2026. This shift challenges the company's investment narrative, which relies on its expanding …

Takeda Korea appoints Kim Mi-seung as new representative director

Takeda Korea has appointed Kim Mi-seung, previously head of its oncology business unit, as its new representative director. This appointment fills a two-month vacancy left after the former General Manager, Park Kwang-kyu, stepped down in June. Kim brings over two decades of experience in …

Organogenesis Holdings, Inc. Class A Revenue Breakdown – MUN:2PQ

Organogenesis Holdings, Inc. Class A (MUN:2PQ) generated €479.37 million in revenue last year, primarily from its Advanced Wound Care segment, which contributed €452.31 million. The majority of this revenue, €479.37 million, originated from the United States market. These figures represent an increase from the …

Farallon Capital Management Trims Liquidia Corp (LQDA) Stake -- Shares Trade 45% Below GF Value

Farallon Capital Management reduced its stake in Liquidia Corp (LQDA) by 3.36%, selling 291,000 shares at $79.73 each. Despite Liquidia's significant year-to-date gain of 189.9% and its stock trading 45% below its GF Value, GuruFocus labels it a "Possible Value Trap," advising caution due …

Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second quarter 2026 results that showed a larger …

(HLN) Risk Channels and Responsive Allocation

This article analyzes Haleon Plc (NYSE: HLN), identifying a strong near-term sentiment that could influence a neutral mid and long-term outlook. It highlights a significant 25.0:1 risk-reward setup, targeting a 7.7% gain against a 0.3% risk. The analysis also provides institutional trading strategies, including …

Emergent BioSolutions cuts FY2026 revenue forecast, triggering securities investigation.

Emergent BioSolutions has significantly lowered its FY2026 revenue guidance, leading to a sharp decline in its stock price and a securities investigation by Levi & Korsinsky. The law firm is examining whether the company's prior optimistic forecasts were misleading, encouraging investors who suffered losses …

TherapeuticsMD Q2 Net Income From Cont Ops US

This article is a placeholder with no content provided beyond the title. Therefore, no meaningful summary can be generated. The title suggests it would have been about TherapeuticsMD's second-quarter net income from continuing operations in the US.

Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $70.7M, Vs. FactSet Est of $70.4M

Harrow, Inc. (HROW) announced its Q2 financial results, reporting revenue of $70.7 million. This figure exceeded the FactSet estimate of $70.4 million. The flash earnings report highlights a positive performance for the company in the second quarter.

Haleon plc (LON:HLN) Receives Average Recommendation of "Hold" from Analysts

Haleon plc (LON:HLN) has received an average "Hold" recommendation from six analysts, with three suggesting a "buy", two a "sell", and one a "hold". The average 12-month price target for the stock is GBX 395.67, with individual targets ranging from GBX 315 to GBX …

Haleon plc (HLN) Investor Outlook: Exploring a 19.58% Potential Upside in the Healthcare Giant

Haleon plc (HLN), a leader in consumer healthcare with a $44.17 billion market cap, is poised for a potential upside of 19.58%. The company demonstrates stable financial health with modest revenue growth, efficient management, and a balanced dividend yield. Favorable analyst ratings, positive technical …

Hims & Hers Health (NYSE:HIMS) Releases Earnings Results, Misses Estimates By $0.32 EPS

Earnings call transcript: Hims & Hers Q2 2026 revenue beats, EPS misses

Harrow: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for Harrow. As the provided content is minimal, no further details can be extracted regarding the financial performance or other specific results.

Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS)

Levi & Korsinsky, LLP is investigating Emergent BioSolutions (EBS) for potential securities law violations after the company significantly cut its FY2026 revenue guidance. The firm encourages investors who lost money on EBS shares to submit their loss information for a free evaluation of their …

Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview

Talphera Inc is projected to report a loss of 7 cents per share in its upcoming earnings announcement. This information is presented as an earnings preview. The full article is available through a subscription service on TradingView.

Harrow Health Sees Strong Q2 Growth, Reaffirms 2026 Outlook

Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading

Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates

Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. …

Tilray Brands Inc. stock falls Monday, underperforms market

Tilray Brands Inc. (TLRY) shares fell 3.28% on Monday, closing at $4.42. This decline occurred during a generally poor trading session, with the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing drops. The stock's fall ended a two-day winning streak.

Scynexis Q2 adjusted EPS misses estimate as sales decline 82.77%

Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Martine Rothblatt, CEO of United Therapeutics (NASDAQ:UTHR), sold 9,500 shares of the company's stock for over $5 million, reducing her stake by 2.84%. The sale occurred on August 7th at an average price of $531.38 per share. Despite the sale, United Therapeutics beat earnings …

Hims & Hers Lowers Profit Forecast, Shares Drop

Hims & Hers Health shares are down after the telehealth firm reduced the top end of its adjusted Ebitda forecast for the full year. Madison Muller reports on "Bloomberg The Close." View Comments

Harrow (NASDAQ:HROW) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS

Harrow (NASDAQ:HROW) reported a quarterly EPS of ($0.46), missing analysts' consensus of ($0.18) by $0.28, despite revenue of $70.66 million slightly exceeding expectations. Shares of HROW traded up 0.6% following the announcement. The company has a "Moderate Buy" consensus rating from analysts, with insider …

Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Buys 10,000 Shares of Stock

Elanco Animal Health (NYSE:ELAN) Director Paul Herendeen recently purchased 10,000 shares of the company's stock for $236,800, increasing his total ownership to 111,687 shares. This insider buying follows Elanco's strong quarterly earnings report, where the company beat estimates with $0.34 EPS and saw revenue …

Prestige Consumer Executives Set for Aug. 12 Fireside Chat

Prestige Consumer Healthcare Inc. (NYSE: PBH) announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Treasury, & Business Development, Phil Terpolilli, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at …

Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference

Prestige Consumer Healthcare Inc. announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Treasury, & Business Development, Phil Terpolilli, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for Wednesday, August …

Hims Hers Health earnings missed by $0.32, revenue topped estimates

Hims & Hers Shares Drop After Beating Revenue Forecast With $753 Million, Margins Narrow